Apitope to Present At the "Therapeutic & Preventative Vaccines for Autoimmune Diseases: Scientific & Commercial Opportunities" Symposium on 9 January 2011, 2.45pm (Pst)

Published: Jan 07, 2011

Bristol, UK / Hasselt, Belgium – 7th January 2011: Apitope International N.V., the biopharmaceutical company developing peptide therapies for autoimmune diseases, is pleased to announce that Dr. Keith Martin, CEO, will provide an update on Apitope (antigen processing independent epitope autoimmune vaccines) at the symposium on “Therapeutic & Preventative Vaccines for Autoimmune Diseases: Scientific & Commercial Opportunities”, sponsored by the Juvenile Diabetes Research Foundation and Fast Forward, LLC.

Dr. Martin will present at the Hilton San Francisco, Union Square, at 2.45pm (PST) on Sunday, 9 January 2011, prior to the J.P. Morgan Healthcare Conference.

The symposium will feature leading researchers and experts on autoimmune vaccines, presenting the latest scientific and technological knowledge and insight into this emerging field.

For further information:

Apitope International N.V. Dr. Keith Martin, CEO +44 (0)117 920 0062 keith.martin@apitope.com

Capital MSL Mary Clark, Head of Life Sciences +44 20 7307 5330 mary.clark@capitalmsl.com

About Apitope

Apitope is a European biotechnology company focusing on the discovery and development of revolutionary disease modifying therapies for treating autoimmune and allergic diseases, including multiple sclerosis, and Graves’ disease. It has headquarters in Hasselt, Belgium and a subsidiary in Bristol, UK.

The Company is developing potential therapies to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non- specifically suppress the whole immune system.

Its patented, leading edge, high speed discovery platform enables it to identify and design innovative peptide-based therapies and diagnostics and it has an impressive pipeline of products in development.

Apitope has a highly experienced management team, with a proven track record in discovering and developing innovative therapeutics. Its lead product for treating multiple sclerosis is in Phase I development and is partnered with Merck Serono, a division of Merck KGaA, Darmstadt, Germany.

For more information, please go to www.apitope.com

Back to news